Evaluation of Treatment by Glofitamab in Combination With Rituximab or Obinutuzumab Plus CHOP in Patients With RIchter Syndrome
Condition(s):Richter SyndromeLast Updated:January 2, 2024Not yet recruiting
Hide Studies Not Open or Pending
Condition(s):Richter SyndromeLast Updated:January 2, 2024Not yet recruiting
Condition(s):Mantle Cell Lymphoma; MCLLast Updated:January 22, 2024Recruiting
Condition(s):Diffuse Large B Cell Lymphoma (DLBCL)Last Updated:March 12, 2024Not yet recruiting
Condition(s):Large B-cell LymphomaLast Updated:October 10, 2023Not yet recruiting
Condition(s):B Cell LymphomaLast Updated:January 19, 2024Not yet recruiting
Condition(s):Diffuse Large B Cell Lymphoma; High-grade B-cell LymphomaLast Updated:August 23, 2023Active, not recruiting
Condition(s):LymphomaLast Updated:January 19, 2024Completed
Condition(s):Diffuse Large B-Cell LymphomaLast Updated:December 18, 2023Recruiting
Condition(s):Non-Hodgkin’s LymphomaLast Updated:March 22, 2024Recruiting
Condition(s):Mantle Cell LymphomaLast Updated:February 12, 2024Not yet recruiting
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.